Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for MLAB and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for MLAB and 80,000+ other tickers.
See exactly how MLAB's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MLAB and 80,000+ other tickers.
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical…
LAKEWOOD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa,” “we,” “us” or “our”), a global leader in the design and manufacture of critical quality control solutions and life sciences tools, today announced a savings plan (the “Savings Plan”) expected to reduce annualized operating costs by approximately $9.3 million.
Mesa Laboratories, Inc. (NASDAQ: MLAB - Get Free Report) shares reached a new 52-week high on Monday. The company traded as high as $139.60 and last traded at $140.8960, with a volume of 78444 shares traded. The stock had previously closed at $132.55. Analyst Ratings Changes A number of equities analysts have issued reports on the
On September 02, 2026, Mesa Laboratories Inc (MLAB) shares rose 4.1% to $130.65, reflecting a significant increase within a volatile 52-week range of $58.83 to
Mesa Laboratories (NASDAQ: MLAB - Get Free Report) and ImmunoPrecise Antibodies (OTCMKTS:IPATF - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations. Earnings and Valuation This table compares Mesa Laboratories
Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript